Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis

Semaglutide Reduces Cardiovascular Risk:
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and in those with overweight or obesity without diabetes.

Clinical Trials:
The SELECT trial demonstrated a 20% reduction in MACE in adults with overweight or obesity and established cardiovascular disease but no history of diabetes.

Post-Hoc Analysis:
Novo Nordisk has revealed additional post-hoc cardiovascular data for semaglutide, further supporting its benefits in reducing cardiovascular risk.

Presentation at ADA Scientific Sessions:
Novo Nordisk presented key findings from semaglutide trials at the 84th Scientific Sessions of the American Diabetes Association (ADA), including data on kidney and cardiovascular endpoints in people with type 2 diabetes and chronic kidney disease.

Broad Therapeutic Potential:
Semaglutide is being explored for its potential to address multiple facets of cardiometabolic conditions, including cardiovascular disease, chronic kidney disease, obesity, and type 2 diabetes.